<?xml version="1.0" encoding="UTF-8"?>
<p>Dengvaxia (also known as CYD-TDV) is the first tetravalent dengue vaccine to be licensed in 2015, but its performance is dependent on the serostatus of the receiving individual [
 <xref rid="B28-molecules-25-02796" ref-type="bibr">28</xref>]. Clinical trials have shown that the vaccine is safe and efficacious in people who previously had a DENV infection (seropositive individuals); however, it confers a predisposition to severe dengue in those who experience their first natural dengue infection after vaccination (seronegative individuals) [
 <xref rid="B27-molecules-25-02796" ref-type="bibr">27</xref>,
 <xref rid="B29-molecules-25-02796" ref-type="bibr">29</xref>]. Therefore, it may not be suitable for everyone to receive the vaccine because of the risk involved. Currently, no specific therapeutic agent exists for dengue and treatment is mainly supportive.
</p>
